Cardiff Oncology (CRDF) News Today $2.53 -0.09 (-3.44%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cardiff Oncology announces new patent with claims for onvansertibNovember 19 at 3:03 PM | markets.businessinsider.comCardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRCNovember 19 at 10:01 AM | markets.businessinsider.comHC Wainwright Cuts Cardiff Oncology (NASDAQ:CRDF) Price Target to $13.00November 12, 2024 | americanbankingnews.comCardiff Oncology price target lowered to $13 from $14 at H.C. WainwrightNovember 9, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)November 8, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for Cardiff Oncology (NASDAQ:CRDF) Stock PriceHC Wainwright dropped their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a "buy" rating for the company in a report on Friday.November 8, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 77.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 270,523 shaNovember 3, 2024 | marketbeat.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Expands By 7.2%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 7,320,000 shares, an increase of 7.2% from the September 30th total of 6,830,000 shares. Based on an average daily volume of 495,200 shares, the days-to-cover ratio is presently 14.8 days.November 1, 2024 | marketbeat.comCardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRCOctober 30, 2024 | globenewswire.comCardiff Oncology Inc (CRDF) Q2 2024 Earnings Call Highlights: Strategic Trials and Financial ...October 9, 2024 | finance.yahoo.comCraig-Hallum Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationSeptember 6, 2024 | msn.comCardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Craig HallumCraig Hallum began coverage on Cardiff Oncology in a research note on Friday. They set a "buy" rating and a $8.00 price objective on the stock.September 6, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Sees Significant Growth in Short InterestCardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 6,720,000 shares, a growth of 16.3% from the July 31st total of 5,780,000 shares. Based on an average daily trading volume, of 573,000 shares, the short-interest ratio is presently 11.7 days.September 2, 2024 | marketbeat.comAssenagon Asset Management S.A. Buys 962,940 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)Assenagon Asset Management S.A. increased its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 380.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,215,922 shareAugust 21, 2024 | marketbeat.comEarnings call: Cardiff Oncology Q2 2024 update on CRDF-004 trial and financesAugust 15, 2024 | uk.investing.comCardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comWhat Wall Street expects from Cardiff Oncology's earningsAugust 7, 2024 | markets.businessinsider.comCardiff Oncology (CRDF) Set to Announce Quarterly Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.August 2, 2024 | marketbeat.comCompanies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In GrowthJuly 24, 2024 | finance.yahoo.comCardiff Oncology (NASDAQ:CRDF) Trading 0.7% Higher Cardiff Oncology (NASDAQ:CRDF) Shares Up 0.7%June 11, 2024 | marketbeat.comCardiff Oncology to Present at the Jefferies Healthcare ConferenceMay 29, 2024 | globenewswire.comAssenagon Asset Management S.A. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)Assenagon Asset Management S.A. acquired a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 252,982 shares of the company's stock,May 20, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest UpdateCardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 4,420,000 shares, an increase of 10.8% from the April 15th total of 3,990,000 shares. Based on an average daily volume of 1,900,000 shares, the short-interest ratio is presently 2.3 days.May 17, 2024 | marketbeat.comCardiff Oncology to Present at Upcoming Investor Conferences in MayMay 13, 2024 | globenewswire.comHC Wainwright Analysts Raise Earnings Estimates for Cardiff Oncology, Inc. (NASDAQ:CRDF)Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Cardiff Oncology in a report released on Monday, May 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings perMay 9, 2024 | marketbeat.comCardiff Oncology (NASDAQ:CRDF) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Cardiff Oncology in a research note on Monday.May 6, 2024 | marketbeat.comCardiff Oncology First Quarter 2024 Earnings: Beats ExpectationsMay 4, 2024 | finance.yahoo.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call TranscriptMay 3, 2024 | msn.comCardiff Oncology Inc (CRDF) (Q1 2024) Earnings Call Transcript Highlights: Strategic Insights ...May 3, 2024 | finance.yahoo.comCRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | investorplace.comCardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateMay 2, 2024 | globenewswire.comCardiff Oncology (CRDF) Set to Announce Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.May 1, 2024 | marketbeat.comCardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateApril 25, 2024 | globenewswire.comCardiff Oncology, Inc. (NASDAQ:CRDF) Forecasted to Earn Q1 2025 Earnings of ($0.28) Per ShareCardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at William Blair issued their Q1 2025 EPS estimates for Cardiff Oncology in a note issued to investors on Tuesday, April 9th. William Blair analyst A. Hsieh anticipates that the company will earn ($0.28) per share for the quarter. TheApril 12, 2024 | marketbeat.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?April 9, 2024 | investorplace.comCardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyApril 8, 2024 | globenewswire.combluebird bio falls as accounting errors force restatementsMarch 27, 2024 | msn.comFinding the Next Big Winners: 3 Stocks You Can Snag for Under $5March 21, 2024 | investorplace.comREGN Mar 2024 982.500 callMarch 16, 2024 | finance.yahoo.comREGN Mar 2024 1010.000 putMarch 16, 2024 | finance.yahoo.comCRDF Apr 2024 2.500 callMarch 15, 2024 | finance.yahoo.comCRDF Nov 2024 10.000 putMarch 15, 2024 | finance.yahoo.comCRDF Apr 2024 5.000 callMarch 15, 2024 | finance.yahoo.comREGN Mar 2024 992.500 callMarch 14, 2024 | finance.yahoo.comCardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)March 8, 2024 | seekingalpha.comHC Wainwright Weighs in on Cardiff Oncology, Inc.'s Q1 2024 Earnings (NASDAQ:CRDF)Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share (EPS) estimates for Cardiff Oncology in a research note issued on Wednesday, March 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.23) per share for tMarch 8, 2024 | marketbeat.comCardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024March 6, 2024 | globenewswire.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Drops By 7.8%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 1,190,000 shares, a drop of 7.8% from the January 31st total of 1,290,000 shares. Based on an average daily volume of 156,900 shares, the days-to-cover ratio is currently 7.6 days.March 4, 2024 | marketbeat.comCardiff Oncology Full Year 2023 Earnings: Beats ExpectationsMarch 3, 2024 | finance.yahoo.comCardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | seekingalpha.com Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. CRDF Media Mentions By Week CRDF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDF News Sentiment▼0.000.45▲Average Medical News Sentiment CRDF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDF Articles This Week▼21▲CRDF Articles Average Week Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADAP News Today ALGS News Today AGEN News Today DTIL News Today STRO News Today ATHA News Today PSTX News Today CRVS News Today SANA News Today GLUE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDF Stock Alerts